Regulus Therapeutics (NASDAQ:RGLS) Lowered to Hold at Zacks Investment Research

Regulus Therapeutics (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other brokerages have also commented on RGLS. Cantor Fitzgerald initiated coverage on shares of Regulus Therapeutics in a research note on Thursday, September 2nd. They set an “overweight” rating and a $2.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 11th.

NASDAQ:RGLS opened at $0.72 on Wednesday. The company has a fifty day moving average of $0.73 and a 200-day moving average of $1.02. The firm has a market capitalization of $62.69 million, a P/E ratio of -3.13 and a beta of 2.22. Regulus Therapeutics has a twelve month low of $0.45 and a twelve month high of $2.32.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Tuesday, August 10th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.08). Equities research analysts anticipate that Regulus Therapeutics will post -0.3 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC bought a new stake in shares of Regulus Therapeutics in the 1st quarter worth $31,000. Lido Advisors LLC bought a new stake in shares of Regulus Therapeutics in the 2nd quarter worth $47,000. Strategic Wealth Advisors Group LLC bought a new stake in shares of Regulus Therapeutics in the 2nd quarter worth $61,000. Northern Trust Corp grew its stake in shares of Regulus Therapeutics by 198.4% in the 1st quarter. Northern Trust Corp now owns 117,654 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 78,223 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Regulus Therapeutics in the 2nd quarter worth $64,000. Hedge funds and other institutional investors own 26.41% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Further Reading: Is it Safe to Invest in Commodities?

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.